Literature DB >> 21234266

PCA3 Urinary Biomarker for Prostate Cancer.

Stacy Loeb1, Alan W Partin.   

Abstract

Entities:  

Year:  2010        PMID： 21234266      PMCID： PMC3020285     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  8 in total

1.  PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Authors:  Ina L Deras; Sheila M J Aubin; Amy Blase; John R Day; Seongjoon Koo; Alan W Partin; William J Ellis; Leonard S Marks; Yves Fradet; Harry Rittenhouse; Jack Groskopf
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

2.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.

Authors:  Jacques B de Kok; Gerald W Verhaegh; Rian W Roelofs; Daphne Hessels; Lambertus A Kiemeney; Tilly W Aalders; Dorine W Swinkels; Jack A Schalken
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

3.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Authors:  Leonard S Marks; Yves Fradet; Ina Lim Deras; Amy Blase; Jeannette Mathis; Sheila M J Aubin; Anthony T Cancio; Marie Desaulniers; William J Ellis; Harry Rittenhouse; Jack Groskopf
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

4.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors:  M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

5.  Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

Authors:  Monique J Roobol; Fritz H Schröder; Pim van Leeuwen; Tineke Wolters; Roderick C N van den Bergh; Geert J L H van Leenders; Daphne Hessels
Journal:  Eur Urol       Date:  2010-07-09       Impact factor: 20.096

6.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Authors:  Alexander Haese; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clément-Claude Abbou; Mesut Remzi; Martina Tinzl; Susan Feyerabend; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

7.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

Authors:  Felix K Chun; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clement-Claude Abbou; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken; Yves Fradet; Leonard S Marks; William Ellis; Alan W Partin; Alexander Haese
Journal:  Eur Urol       Date:  2009-03-13       Impact factor: 20.096

8.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
  8 in total
  3 in total

1.  Review of the literature: PCA3 for prostate cancer risk assessment and prognostication.

Authors:  Stacy Loeb; Alan W Partin
Journal:  Rev Urol       Date:  2011

Review 2.  Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives.

Authors:  Felice Crocetto; Gianluca Russo; Erika Di Zazzo; Pasquale Pisapia; Benito Fabio Mirto; Alessandro Palmieri; Francesco Pepe; Claudio Bellevicine; Alessandro Russo; Evelina La Civita; Daniela Terracciano; Umberto Malapelle; Giancarlo Troncone; Biagio Barone
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

3.  Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma.

Authors:  Ádamo Davi Diógenes Siena; Isabela Ichihara de Barros; Camila Baldin Storti; Carlos Alberto Oliveira de Biagi Júnior; Larissa Anastacio da Costa Carvalho; Silvya Stuchi Maria-Engler; Josane de Freitas Sousa; Wilson Araújo Silva
Journal:  J Cell Mol Med       Date:  2022-01-18       Impact factor: 5.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.